Sjö gren's syndrome (SS) is an autoimmune disease that may infrequently be associated with occasionally severe nervous system complications, 1 similar to the neuropsychiatric complications of systemic lupus erythematosus. This patient developed a chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) refractory to i.v. high-dose immunoglobulins, considered the gold standard therapy for this condition. 2 CIDP is an autoimmune disease consisting of a sensory-motor neurological syndrome thought to be due to the interaction of cellular and humoral autoaggressive responses. The result is demyelination, leading to axonal degeneration and long-term disability. In view of the results obtained by means of autologous HSCT in a great variety of severe autoimmune diseases, the procedure has also been utilized in severe refractory cases of CIDP. The first report was published in 2002 3 with initially good results, but the patient relapsed 5 years later. 4 Other cases, including three of his own, have been reviewed by Kazmi et al.
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Our female patient, 29 years old at the time of writing, suffered from recurrent polyarthralgias and recurrent bouts of fever from infancy, developed exudative pericarditis, and was hospitalized, and thereafter followed at the Gaslini Pediatric Clinic of the University of Genoa, Italy. At the age of 14, she was found with marked eye dryness, Raynaud's phenomenon and positive Schirmer's tests. Hypoechoic nodules were found in both parotids. High-titered, fine-speckled antinuclear antibodies (ANAs) were present. They were shown to consist of anti-SS-A (Ro) and anti-SS-B (La) Abs by counterimmunoelectrophoresis. At 22, she was admitted to our unit, having developed bilateral pleural effusions and an anasarcatic state without a clinically demonstrable nephropathy. She also developed a severe sensimotor polyradiculoneuropathy, which required the use of a wheelchair. A series of electromyographic examinations were indicative of a polyradiculoneuropathy with axonal demyelination, consistent with the electrodiagnostic criteria for CIDP. 6 Owing to refractoriness to repeated courses of high-dose immunoglobulins, she received an auto-HSCT consisting of 304 Â 10 6
CD34
þ cells/kg, following conditioning with thiotepa (5 mg/kg) on each of the 2 consecutive days, and 100 mg/kg of CY for 2 days plus G-CSF; she had a 6-month-long remission (able to walk), relapsed and developed pancytopenia with Hb 86 g/L, WBC 11 Â 10 9 /L, Plt 12 Â 10 9 /L. BM histology/cytology was consistent with the diagnosis of severe aplastic anemia. She received an allo-SCT from her HLA-identical sister after conditioning with fludarabine 30 mg/m 2 for 4 days and CY 300 mg/m 2 for 4 days plus TBI 200 cGY. Engraftment was normal, with complete donor chimerism (assessed by STR-PCR profile analysis at day þ 34); she developed grade II GVHD limited to the skin, which responded promptly to steroid therapy. However, walking difficulties persisted, and she received an additional three cycles of highdose immunoglobulins. At present (June 2012), the patient walks and mucosal dryness has disappeared. However, erythrocyte sedimentation rate is still high, and ANAs, of the fine-speckled type, persist with titers ranging from 1:80 to 1:320. A minimal corticotherapy (prednisolone 8 mg on alternate days) is still given. The clinical course of this patient is shown in Table 1 . Following this intensive combined therapy, the clinical signs and symptoms of SS have completely disappeared. However, humoral inflammation and positive ANAs persist, most probably due to the contribution of long-lived plasma cells. 7 Whether the persistence of ANAs may be an indicator of possible future relapses 8 cannot be established at this time. In a patient with SS complicated by a malignant lymphoma, auto-HSCT was followed by cure of the lymphoma but not of the SS. 9 A similar pattern has been recently found by us in systemic lupus erythematosus patients having developed malignant lymphomas. 10 The neurological complication (CIDP) was considerably ameliorated by auto-HSCT, allowing progression from wheelchair to walking. The development of severe aplastic anemia following auto-HSCT poses an additional problem. Severe aplastic anemia is generally considered to be an autoimmune myelopathy. Secondary ADs have been reported following both auto-and allo-HSCT for primary ADs. 11 The sequence of three ADs in this patient strongly suggests a genetic background, and the switch from one AD to the other is reminiscent of Shoenfeld's kaleidoscope of the autoimmune mosaic. 12 
